Catalog No.
DHB94404
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Concentration
1.3mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01375
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CNTO 148, CAS: 476181-74-5
Clone ID
Golimumab
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes, PMID: 33207093
[Golimumab], PMID: 23961671
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, PMID: 23735746
Golimumab, PMID: 20065639
Golimumab in the treatment of psoriatic arthritis, PMID: 30221556
Golimumab (anti-TNF monoclonal antibody): where we stand today, PMID: 33369527
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis, PMID: 23770005
Golimumab in inflammatory bowel diseases: present and future scenarios, PMID: 30206776
Golimumab: A Review in Inflammatory Arthritis, PMID: 28530020
Golimumab for the treatment of ulcerative colitis, PMID: 28472597
Golimumab for the treatment of axial spondyloarthritis, PMID: 27817204
Golimumab for rheumatoid arthritis, PMID: 20091667
Golimumab for moderately to severely active ulcerative colitis, PMID: 27498886
Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis, PMID: 32447529
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study, PMID: 19066176
A review on golimumab in the treatment of psoriatic arthritis, PMID: 28838285
[Golimumab Therapy in Ulcerative Colitis], PMID: 26907481
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, PMID: 19560810
Golimumab, PMID: 19721444
Golimumab for treatment of axial spondyloarthritis, PMID: 26798943
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis, PMID: 30943133
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence, PMID: 30555013
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial, PMID: 18975305
Golimumab for the treatment of axial spondyloarthritis, PMID: 26523483
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis, PMID: 32193187
Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody, PMID: 32781480
Golimumab, the newest TNF-α blocker, comes of age, PMID: 25602858
Golimumab for moderate to severe ulcerative colitis, PMID: 28276288
Golimumab for the treatment of psoriatic arthritis, PMID: 21609657
Golimumab and immunogenicity? 2010 and beyond, PMID: 21612149
Golimumab for rheumatoid arthritis: a systematic review, PMID: 20436075
Intravenous golimumab in rheumatoid arthritis, PMID: 24831189
Golimumab: clinical update on its use for ulcerative colitis, PMID: 25876561
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis, PMID: 28374338
Golimumab and malignancies: true or false association?, PMID: 20373059
Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results, PMID: 32550760
Adverse effects of golimumab in the treatment of rheumatologic diseases, PMID: 23984970
An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis, PMID: 27468228
Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis, PMID: 26811250
Letter: golimumab efficacy in patients with Crohn's disease and concomitant severe arthritis, PMID: 32445531
Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal, PMID: 23580355
Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany, PMID: 32722921
Whither Type 1 Diabetes?, PMID: 33207099
Golimumab therapy of rheumatoid arthritis: an overview, PMID: 20618765
Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis, PMID: 20118145
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, PMID: 19489653
[Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome], PMID: 33331313
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA, PMID: 32755721
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?, PMID: 25829189
Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials, PMID: 27445459
For research use only. Not for human or drug use.
